Professional
Added to YB: 2024-02-29
Pitch date: 2024-02-22
IONS [bullish]
Ionis Pharmaceuticals, Inc.
+83.31%
current return
Author Info
No bio for this author
Company Info
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Market Cap
$13.4B
Pitch Price
$44.09
Price Target
62.00 (-23%)
Dividend
N/A
EV/EBITDA
-55.53
P/E
-51.28
EV/Sales
13.67
Sector
Biotechnology
Category
growth
Ionis Pharmaceuticals, Inc.: Maintaining $62 Fair Value Estimate; Wainua a Precursor to Two Independent Launches
IONS: FV $62. Rev +34% in '23, Spinraza royalties stable at $240M. Wainua for ATTR-PN to compete w/ ALNY's Amvuttra pre cardiomyopathy expansion. Olezarsen for FCS in '24 & donidalorsen for HAE in '25 could be 50% of $4.7B '32 revs. Neuro pipeline w/ BIIB & others support narrow moat vs gene editing. $2B cash, $1.2B debt end '22. Focus on rare neuro launches, profitable in '26 on diversification.
Read full article (9 min)